The Twice-Yearly Shot Called the Closest Thing to an HIV Vaccine — and the Fight Over Who Can Get It

A new injectable drug that requires only two doses a year is being described as the closest the world has ever come to an HIV vaccine, yet its promise is colliding with hard questions about money, patents and political will.

The treatment was the focus of a report by Al Jazeera's Mikail Malik, who examined the widening debate over access to a prevention tool that could reshape the global fight against HIV. The report, broadcast on Al Jazeera's NewsFeed programme, frames the injection as a potential turning point — provided the people who need it most can actually obtain it.

Unlike daily oral pills, which have formed the backbone of HIV prevention for years, the new approach works by delivering protection through a pair of injections spaced across twelve months. That dosing schedule removes one of the biggest obstacles in prevention medicine: the need for near-perfect daily adherence.

Public health experts have long argued that adherence is the weak link in oral prevention. People who take a pill every day can achieve very high levels of protection, but real-world results are often undermined by missed doses, stigma, supply interruptions and the sheer difficulty of maintaining a daily routine over years. A twice-yearly shot sidesteps much of that burden.

The injectable has therefore been greeted with unusual excitement. Malik's report notes that it has been called the closest thing yet to an HIV vaccine — a description that carries weight in a field where a conventional vaccine has remained out of reach after four decades of research.

But the same report makes clear that scientific success does not automatically translate into public access. The central tension is between the drug's transformative potential and the price at which it is sold.

Campaigners argue that a prevention tool of this magnitude should be treated as a global public good, not as a premium product available mainly to patients in wealthy countries. The report highlights concerns about pharmaceutical power and the influence companies hold over pricing and distribution.

Those concerns are sharpened by the fact that much of the underlying research and development was supported by public money. When taxpayers help fund a breakthrough, advocates say, they should not then be asked to pay monopoly prices for the resulting product.

The pricing debate is unfolding against a backdrop of shrinking global health funding. Budgets for international HIV programmes have come under strain in recent years, and the report points to this squeeze as a major obstacle to rolling out any new prevention method at the scale required.

Even a highly effective injection will do little to change the trajectory of the epidemic if it reaches only a small fraction of the people at substantial risk of infection. Epidemiologists consistently identify the same priority groups: adolescent girls and young women in parts of sub-Saharan Africa, men who have sex with men, sex workers, people who inject drugs and others who face both high exposure and limited access to services.

For these populations, a long-acting option could be genuinely life-changing. It reduces the number of clinic visits required, offers privacy that daily pill bottles do not, and removes the daily reminder that can expose users to stigma or coercion.

Yet the very features that make the injection attractive also make it expensive to produce and distribute at scale. Manufacturing capacity, cold-chain requirements and the need for trained health workers all add to the cost of delivery, particularly in low- and middle-income countries.

The report raises a further question that goes beyond this single drug: how the global health system decides who gets access to the next generation of medical breakthroughs. The answer typically depends less on need than on negotiating power, patent law and the willingness of governments to intervene.

Some countries have used compulsory licensing and generic production to bring down the cost of HIV medicines in the past, and activists are pressing for similar tools to be applied here. Voluntary licensing agreements, tiered pricing and advance purchase commitments are among the mechanisms under discussion.

The stakes are considerable. Decades of investment in testing, treatment and prevention have driven major reductions in HIV-related deaths and new infections in many regions, but progress has stalled in others. A prevention method that is easy to use and highly effective could reignite that momentum — or, if access remains unequal, deepen the divide between those who can afford protection and those who cannot.

Malik's report does not present the injection as a silver bullet. It situates the drug within a wider argument about public money, corporate influence and the sustainability of global health financing — an argument that will determine whether a medical milestone becomes a public health achievement or another example of innovation that never reaches the people it was meant to serve.

The question in the headline is, for now, unanswered: the science appears ready, but the systems that decide who receives it are not.